MADRID, May 26 (Reuters) - Spain’s PharmaMar said on Wednesday its first trials of its Aplidin drug on hospitalised patients with moderate COVID-19 showed clinical effects and met safety standards.
The results of these first tests allowed to company to secure Spanish regulatory approval to carry out a late-stage trial on patients in a Phase III trial last month.
“The company has decided to share this data, which demonstrates the therapeutic potential of this drug, with the entire scientific and medical communities, along with patients,” PharmaMar said in a statement.
Britain’s medical regulator authorised the trials two months ago after the journal Science published a paper showing the drug had encouraging antiviral results during in vitro testing.
Aplidin is a drug developed by PharmaMar originally to treat cancer, but has an effect as an antiviral.
Shares of PharmaMar were up 1% to 80.70 euros ($98.75) in early trading.
$1 = 0.8172 euros Reporting by Inti Landauro; editing by Jason Neely